阿托伐他汀钙治疗高龄慢性肾病的临床效果及安全性  

Clinical efficacy and safety of Atorvastatin Calcium in the treatment of elderly patients with chronic kidney disease

作　　者：王萍[1] 曾敏[1] 蒙绪卿[1] 符秀虹[1] 何扬利[1] 陈积雄[1] 孙晓敏[2] 

机构地区：[1]海南省人民医院医疗保健中心,海南海口570311 [2]南方医科大学中医药学院,广东广州510515

出　　处：《中国医药导报》2017年第12期168-171,共4页China Medical Herald

摘　　要：目的观察阿托伐他汀钙治疗高龄慢性肾病的临床效果及安全性。方法选取2014年8月~2015年8月在海南省人民医院医疗保健中心住院的年龄≥80岁的高龄慢性肾病患者120例作为研究对象,采取随机数字表分成对照组和治疗组,各60例。对照组给予常规治疗,治疗组在常规治疗的基础上加用阿托伐他汀钙20 mg,每天1次。治疗前与治疗后6个月检测并比较两组患者三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDLC)、尿酸(UA)、尿素氮(BUN)、血肌酐(Scr)、24 h尿蛋白、肾小球滤过率(GFR)水平,并记录用药期间的不良反应。结果治疗后6个月,两组TG、TC、LDL-C、UA、BUN、Scr、24 h尿蛋白水平均较治疗前明显下降,GFR较治疗前明显上升,差异有统计学意义(P<0.05或P<0.01);治疗后6个月,治疗组TG、TC、LDL-C和UA、BUN、Scr、24 h尿蛋白水平均显著低于对照组,GFR显著高于对照组,差异均有统计学意义(P<0.01或P<0.05)。两组患者在用药期间未发现药物相关性肝损害、横纹肌溶解等,仅治疗组有1例轻微肌痛,1例轻微头痛,未经特殊处理,3 d后症状自行恢复正常。结论阿托伐他汀钙在治疗高龄慢性肾病患者中,除调脂外,还可降低血UA、BUN、Scr、尿蛋白,升高GFR,从而延缓肾功能不全进展,且毒副反应少,安全性好。Objective To observe the clinical efficacy and safety of Atorvastatin Calcium in the treatment of elderly patients with chronic kidney disease. Methods One hundred and twenty elderly patients with chronic kidney disease aged ≥80 years old hospitalized in Medical Health Care Center, Hainan People＇s Hospital from August 2014 to August 2015 were selected as research objects, and they were divided into control group and treatment group by random num- ber table, with 60 cases in each group. The control group was given conventional treatment, on the basis of convention- al treatment, the treatment group as added with Atorvastatin Calcium 20 rag, once a day. Before treatment and 6 months after treatment, the levels of triglyceride （TG）, total cholesterol （TC）, low density lipoprotein cholesterin （LDL-C）, uric acid （UA）, blood urea nitrogen （BUN）, serum creatinine （Set）, 24 hour urine protein and glomerular filtration rate （GFR） of the two groups were detected and compared. The drug adverse reactions during administration were recorded. Results After treatment for 6 months, the levels of TG, TC, LDL-C, UA, BUN, Scr and 24 hours urinary protein in the two groups were significantly decreased compared with those before treatment, the levels of GFR were significantly increased compared with those before treatment, the differences were all statistically significant （P 〈 0.05 or P 〈 0.01）. After treatment for 6 months, the levels of TG, TC, LDL-C, UA, BUN, Ser and 24 hours urinary protein in the treatment group were all lower than those of control group, GFR was higher than that of control group, the differences were all statistically significant （P 〈 0.01 or P 〈 0.05）. Both groups had no drug related liver damage, rhabdomyolysis, and so on during administration, only treatment group had 1 case with mild muscle pain, 1 case with mild headache, without special treatment, symptoms returned to normal after 3 days. Conclusion Atorvastatin Calcium in the treatment of elderly patients

关 键 词：阿托伐他汀钙 高龄 慢性肾病 临床疗效 安全性 

分 类 号：R692[医药卫生—泌尿科学]